Select therapeutic use:
Indications for Pentostatin:
Active hairy cell leukemia.
Ensure adequate hydration. Give as IV bolus or infuse over 20–30 minutes after dilution. 4mg/m2 every other week. Reevaluate after 6 months; discontinue if complete or partial response not achieved; max duration of therapy 12 months. Withhold dose if ANC <200 cells/mm3; may resume when resolved.
Active infections; treat prior to initiating therapy. Withhold or discontinue therapy if severe rash or neurotoxicity develops. Renal impairment. Monitor and obtain CBCs, liver, and renal function before and during therapy. Pregnancy (Cat. D); avoid use. Nursing mothers: not recommended.
Concomitant fludarabine: not recommended. Potentiates vidarabine. Acute pulmonary toxicity and hypotension with carmustine, etoposide, and high dose cyclophosphamide (see literature).
GI upset, fever, rash, fatigue, leukopenia, pruritus, cough, myalgia, chills, headache, abdominal pain, anorexia, asthenia, stomatitis, rhinitis, dyspnea, anemia, pain, sweating, infections, thrombocytopenia.